TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.06nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.74nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.90nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.17nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.34nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.38nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.65nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 5.71nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.33nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.36nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.38nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.45nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.60nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.62nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.71nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.76nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.97nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.10nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.24nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.35nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.44nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.66nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.11nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.16nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.31nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.40nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.67nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.71nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.91nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.92nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 9.14nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 9.23nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 9.48nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 9.5nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 9.51nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 10nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 10.1nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 10.1nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 10.3nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 10.6nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 10.9nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 10.9nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 10.9nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 11nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 11.3nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 11.3nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 11.3nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 11.5nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 11.7nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair
TargetATR-interacting protein/Serine/threonine-protein kinase ATR(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 11.8nMAssay Description:To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo...More data for this Ligand-Target Pair